Literature DB >> 21962729

Hypertrophic cardiomyopathy.

Steve R Ommen.   

Abstract

Hypertrophic cardiomyopathy is a fascinating disease of marked heterogeneity. Hypertrophic cardiomyopathy was originally characterized by massive myocardial hypertrophy in the absence of known etiology, a dynamic left ventricular outflow obstruction, and increased risk of sudden death. It is now well accepted that multiple mutations in genes encoding for the cardiac sarcomere are responsible for the disease. Complex morphologic and pathophysiologic differences, disparate natural history studies, and novel treatment strategies underscore the challenge to the practicing cardiologist when faced with the management of the hypertrophic cardiomyopathy patient.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21962729     DOI: 10.1016/j.cpcardiol.2011.06.001

Source DB:  PubMed          Journal:  Curr Probl Cardiol        ISSN: 0146-2806            Impact factor:   5.200


  9 in total

1.  Characterization of macrolesions induced by myocardial cavitation-enabled therapy.

Authors:  Yiying I Zhu; Douglas L Miller; Chunyan Dou; Oliver D Kripfgans
Journal:  IEEE Trans Biomed Eng       Date:  2014-10-22       Impact factor: 4.538

2.  TMT-based quantitative proteomics reveals protein biomarkers from cultured Pacific abalone (Haliotis discus hannai) in different regions.

Authors:  Yimu Luan; Yonghui Dong; Xuyuan Duan; Xiuli Wang; Yue Pang; Qingwei Li; Meng Gou
Journal:  Food Chem X       Date:  2022-06-03

3.  Pregnancy in women with hypertrophic cardiomyopathy.

Authors:  P G Pieper; F Walker
Journal:  Neth Heart J       Date:  2013-01       Impact factor: 2.380

4.  Postnatal ablation of Foxm1 from cardiomyocytes causes late onset cardiac hypertrophy and fibrosis without exacerbating pressure overload-induced cardiac remodeling.

Authors:  Craig Bolte; Yufang Zhang; Allen York; Tanya V Kalin; Jo El J Schultz; Jeffery D Molkentin; Vladimir V Kalinichenko
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

5.  miR-139-5p inhibits isoproterenol-induced cardiac hypertrophy by targetting c-Jun.

Authors:  Su Ming; Wang Shui-Yun; Qiu Wei; Li Jian-Hui; Hui Ru-Tai; Song Lei; Jia Mei; Wang Hui; Wang Ji-Zheng
Journal:  Biosci Rep       Date:  2018-03-09       Impact factor: 3.840

6.  Defining genotype-phenotype relationships in patients with hypertrophic cardiomyopathy using cardiovascular magnetic resonance imaging.

Authors:  Robert J H Miller; Shahriar Heidary; Aleksandra Pavlovic; Audrey Schlachter; Rajesh Dash; Dominik Fleischmann; Euan A Ashley; Matthew T Wheeler; Phillip C Yang
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

7.  Left ventricular strain patterns and their relationships with cardiac biomarkers in hypertrophic cardiomyopathy patients with preserved left ventricular ejection fraction.

Authors:  Lisha Zhang; Yixuan Wan; Bo He; Lei Wang; Dongyong Zhu; Fabao Gao
Journal:  Front Cardiovasc Med       Date:  2022-10-04

8.  MiR-451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1.

Authors:  Lei Song; Ming Su; Shuiyun Wang; Yubao Zou; Xiaojian Wang; Yilu Wang; Hongli Cui; Peng Zhao; Rutai Hui; Jizheng Wang
Journal:  J Cell Mol Med       Date:  2014-09-11       Impact factor: 5.310

9.  Zinc finger protein 91 loss induces cardiac hypertrophy through adenosine A1 receptor down-regulation under pressure overload status.

Authors:  Xiangqi Wu; Wei You; Zhiming Wu; Fei Ye; Shaoliang Chen
Journal:  J Cell Mol Med       Date:  2020-07-17       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.